Linezolid (Zyvoxid®);Le linézolide (Zyvoxid®)

Revue Medicale de Bruxelles

Volumn 25, Issue 1, 2004, Pages 47-50

  Van Laethem, Y ^a   Sternon, J ^b  

^a SAINT PIERRE UNIVERSITY HOSPITAL   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Clinical and bacteriological efficacy; Linezolid; Oral and intravenous administration; Severe gram positive infections

Indexed keywords

CEFTRIAXONE; CITALOPRAM; FLUOXETINE; FLUVOXAMINE MALEATE; LINEZOLID; MONOAMINE OXIDASE INHIBITOR; PAROXETINE; SERTRALINE; VANCOMYCIN;

ABDOMINAL INFECTION; ANEMIA; ANTIBIOTIC RESISTANCE; BACTERIAL INFECTION; BONE MARROW SUPPRESSION; DIARRHEA; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG INDICATION; FEBRILE NEUTROPENIA; HEADACHE; HUMAN; LEUKOPENIA; LUNG INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NAUSEA; OSTEITIS; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; THROMBOCYTOPENIA; URINARY TRACT INFECTION; VOMITING;

ACETAMIDES; ANTI-INFECTIVE AGENTS; HUMANS; OXAZOLIDINONES;

EID: 1542268313     PISSN: 00353639     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (39)

1. Henwood CJ, Livermore DM, Johnson AP, James D, Warner M, Gardiner A, and the Linezolid Study Group: Susceptibility of Gram-positive cocci from 25 UK hospitals to antimicrobial agents including linezolid. J Antimicrob Chemother 2000; 46: 931-40
2. Moellering Jr RC: Linezolid: the first oxazolidinone antimicrobial. Ann Intern Med 2003; 138: 135-42
3. Livermore DM: Linezolid in vitro: mechanism and antibacterial spectrum. J Antimicrob Chemother 2003; 51 (Suppl S2): 9-16
4. Tsiodras S, Gold HS, Sakoulas G et al: Linezolid resistance in a clinical isolate of Staphylococcus aureus. Lancet 2001; 358: 207-8
5. Gonzales RD, Schreckenberger PC, Graham MB, Kelkar S, DenBesten K, Quinn JP: Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid. Lancet 2001; 357: 1179
6. Zurenko GE, Yagi BH, Schaadt RD et al: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996; 40: 839-45
7. Wilcox MH: Efficacy of linezolid versus comparator therapies in Gram-positive infections. J Antimicrob Chemother 2003; 51 (Suppl S2): 27-35
8. Birmingham MC, Rayner CR, Meagher HK, Flavin SM, Batts DH, Schentag JJ: Linezolid for the treatment of multidrug-resistant, Gram-positive infections: experience from a compassionate-use program. CID 2003; 36: 159-68
9. Khoury JE, Fishman JA: Linezolid in the treatment of vancomycin-resistant Enterococcus faecium in solid organ transplant recipients: report of a multicenter compassionate use trial. Transpl Infect Dis 2003; 5: 121-5
10. European Committee on Antimicrobial Susceptibility Testing (EUCAST) of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID): Linezolid breakpoints. Clin Microbiol Infect 2001; 7: 283-4
11. Welshman IR, Sisson TA, Jungbluth GL, Stalker DJ, Hopkins NK: Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos 2001; 22: 91-7
12. Andes D, van Ogtrop ML, Peng J, Craig WA: In vivo pharmacodynamics of a new oxazolidinone (linezolid). Antimicrob Agents Chemother 2002; 46: 3484-9
13. Rayner CR, Forrest A, Meagher AK, Birmingham MC, Schentag JJ: Clinical pharmacodynamics in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet 2003; 42: 1411-23
14. Gee T, Ellis R, Marshall G, Andrews J, Ashby J, Wise R: Pharmacokinetics and tissue penetration of linezolid following multiple oral doses. Antimicrob Agents Chemother 2001; 45: 1643-6
15. Conte Jr JE, Golden JA, Kipps J, Zurlinden E: Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2003; 46: 1475-80
16. Lovering AM, Zhang J, Bannister GC et al: Penetration of linezolid into bone, fat, muscle and haematoma of patients ondergoing routine hip replacement. J Antimicrob Chemother 2002; 50: 73-7
17. 14C] linezolid to healthy human subjects. Drug Metab Dispos 2001; 29: 1136-45
18. Slatter JG, Adams LA, Bush EC et al: Pharmacokinetics, toxikinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 2002; 32: 907-24
19. San Pedro GS, Cammarata SK, Oliphant TH, Todisco T, and the linezolid community-acquired pneumonia study group: Linezolid versus ceftriaxone/cefpodoxime in patients hospitalized for the treatment of Streptococcus pneumoniae pneumonia. Scand J Infect Dis 2002; 34: 720-8
20. Rubinstein E, Cammarata SK, Oliphant TH, Wunderink RG, and the Linezolid Nosocomial Pneumonia Study Group: Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. Clin Infect Dis 2001; 32: 402-12
21. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH for the linezolid nososcomial pneumonia study group: Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther 2003; 25: 980-92
22. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B, and the linezolid MRSA study group: Linezolid versus vancumycin for the treatment of methicillin-resistnant Straphylococcus aureus infection. Clin Infect Dis 2002; 34: 1481-90
23. Stevens DL, Smith LG, Bruss JB et al for the Linezolid Skin and Soft Tissue Infections Study Group: Randomized comparison of linezolid (PNU-100766) versus oxacillin/dicloxacillin for treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother 2000; 44: 3408-13
24. Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH: Linezolid vs vancomycin. Analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003; 124: 1789-97
25. Smith PF, Birmingham MC, Noskin GA et al: Safety, efficacy and pharmacokinetics of linezolid for treatment of resistant Gram-positive infections in cancer patients with neutropenia. Ann Oncol 2003; 14: 795-801
26. Brier ME, Stalker DJ, Aronoff GR et al: Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003; 47: 2775-80
27. Li Z, Willke RJ, Pinto LA et al: Comparison of length of hospital stay for patients with known or suspected Staphylococcus species infections treated with linezolid or vancomycin: a randomized, multicenter trial. Pharmacother 2001; 21: 263-74
28. Wilson P, Andrews JA, Charlesworth R et al: Linezolid resistance in clinical isolates of Staphylococcus aureus. J Antimicrob Chemother 2003; 51: 186-7
29. Melzer M, Goldsmith D, Gransden W: Successful treatment of vertebral osteomyelitis with linezolid in a patient receiving hemodialysis and with persistent methicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus bacteremias. CID 2000; 31: 208-9
30. Till M, Wixson RL, Pertel PE: Linezolid treatment for osteomyelitis due to vancomycin-resistant Enterococcus faecium. CID 2002; 34: 1412-4
31. Moise AP, Forest A, Birmingham MC, Schentag JJ: The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to vancomycin. J Antimicrobial Chemother 2002; 50: 1017-26
32. Rubinstein E, Isturiz R, Standiford AC et al: Worldwide assessment of linezolid's clinical safety and tolerability: comparator-controlled phase III studies. Antimicrob Agents Chemother 2003; 47: 1824-31
33. Gerson SL, Kaplan SL, Bruss JB: Hematologic effects of linezolid: summary of clinical experience. Antimicrob Agents Chemother 2002; 46: 2723-6
34. Orrick JJ, Johns T, Janelle J, Ramphal R, Thrombocytopenia secondary to linezolid administration: what is the risk? Clin Infect Dis 2002; 35: 348-9
35. Attassi K, Hershberger E, Alam R, Zervos MJ: Thrombocytopenia associated with linezolid therapy. Clin Infect Dis 2002; 34: 695-8
36. Nasraway SA, Shorr AF, Kuter DJ, O'Grady N, Le, VH, Cammarata SK: Linezolid does not increase the risk of thrombocytopenia in patients with nosocomial pneumonia: comparative analysis of linezolid and vancomycin use. Clin Infect Dis 2003; 11: 1609-16
37. Bernstein WB, Trotta RF, Rectore JT, Tjaden JA, Barile AJ: Mechanisms for linezolid-induced anemia and thrombocytopenia. Ann Pharmacother 2003; 37: 517-20
38. Antal JD, Hendershot PE, Batts DH, Sheu WP, Hopkins NK, Donaldson KM: Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol 2001; 41: 552-62
39. Hendershot PE, Antal EJ, Welshman IR, Batts DH, Hopkins NK: Linezolid: pharmacokinetic and pharmacodynamic evaluation of coadministration with pseudoephedrine HCl, phenylpropanolamine HCl, and dextromethorphan HBr. J Clin Pharmacol 2001; 41: 563-72